Royal Bank of Canada’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $667K | Buy |
30,555
+7,174
| +31% | +$149K | ﹤0.01% | 4138 |
|
|
2026
Q1 | $546K | Sell |
23,381
-1,959
| -8% | -$42.6K | ﹤0.01% | 4071 |
|
|
2025
Q4 | $532K | Sell |
25,340
-202,660
| -89% | -$3.54M | ﹤0.01% | 4109 |
|
|
2025
Q3 | $3.51M | Sell |
228,000
-123,263
| -35% | -$1.61M | ﹤0.01% | 2948 |
|
|
2025
Q2 | $3.29M | Buy |
351,263
+349,342
| +18,185% | +$3.85M | ﹤0.01% | 2913 |
|
|
2025
Q1 | $24K | Sell |
1,921
-348
| -15% | -$4.91K | ﹤0.01% | 5859 |
|
|
2024
Q4 | $30K | Sell |
2,269
-7,108
| -76% | -$122K | ﹤0.01% | 5934 |
|
|
2024
Q3 | $181K | Buy |
9,377
+1,162
| +14% | +$24K | ﹤0.01% | 4896 |
|
|
2024
Q2 | $169K | Buy |
8,215
+6,229
| +314% | +$130K | ﹤0.01% | 4899 |
|
|
2024
Q1 | $47K | Sell |
1,986
-17,376
| -90% | -$388K | ﹤0.01% | 5572 |
|
|
2023
Q4 | $418K | Buy |
19,362
+7,883
| +69% | +$121K | ﹤0.01% | 4416 |
|
|
2023
Q3 | $167K | Buy |
11,479
+4,126
| +56% | +$78K | ﹤0.01% | 4968 |
|
|
2023
Q2 | $154K | Buy |
7,353
+1,202
| +20% | +$25K | ﹤0.01% | 4974 |
|
|
2023
Q1 | $129K | Sell |
6,151
-3,327
| -35% | -$82.8K | ﹤0.01% | 4974 |
|
|
2022
Q4 | $241K | Buy |
9,478
+5,856
| +162% | +$137K | ﹤0.01% | 4718 |
|
|
2022
Q3 | $87K | Buy |
3,622
+3,331
| +1,145% | +$74.7K | ﹤0.01% | 5405 |
|
|
2022
Q2 | $6K | Sell |
291
-2,725
| -90% | -$45.4K | ﹤0.01% | 6595 |
|
|
2022
Q1 | $52K | Sell |
3,016
-5,715
| -65% | -$96.2K | ﹤0.01% | 6068 |
|
|
2021
Q4 | $192K | Buy |
8,731
+8,276
| +1,819% | +$153K | ﹤0.01% | 5373 |
|
|
2021
Q3 | $9K | Sell |
455
-2,623
| -85% | -$43.7K | ﹤0.01% | 7010 |
|
|
2021
Q2 | $53K | Buy |
3,078
+548
| +22% | +$10K | ﹤0.01% | 6002 |
|
|
2021
Q1 | $57K | Buy |
2,530
+2,259
| +834% | +$51K | ﹤0.01% | 5803 |
|
|
2020
Q4 | $6K | Buy |
271
+235
| +653% | +$4.87K | ﹤0.01% | 6592 |
|
|
2020
Q3 | $1K | Sell |
36
-1,506
| -98% | -$23K | ﹤0.01% | 6476 |
|
|
2020
Q2 | $23K | Sell |
1,542
-69
| -4% | -$1.05K | ﹤0.01% | 5541 |
|
|
2020
Q1 | $18K | Sell |
1,611
-44
| -3% | -$413 | ﹤0.01% | 5593 |
|
|
2019
Q4 | $15K | Buy |
+1,655
| New | +$12.2K | ﹤0.01% | 5993 |
|
|
2018
Q4 | – | Sell |
-1,026
| Closed | -$8K | – | 7085 |
|
|
2018
Q3 | $8K | Sell |
1,026
-517
| -34% | -$3.69K | ﹤0.01% | 6078 |
|
|
2018
Q2 | $11K | Buy |
1,543
+643
| +71% | +$6.31K | ﹤0.01% | 5795 |
|
|
2018
Q1 | $13K | Buy |
900
+871
| +3,003% | +$9.24K | ﹤0.01% | 5630 |
|
|
2017
Q4 | $0 | Sell |
29
-804
| -97% | -$7.96K | ﹤0.01% | 6851 |
|
|
2017
Q3 | $10K | Buy |
833
+797
| +2,214% | +$9.77K | ﹤0.01% | 6272 |
|
|
2017
Q2 | $1K | Sell |
36
-200
| -85% | -$2.29K | ﹤0.01% | 6432 |
|
|
2017
Q1 | $3K | Sell |
236
-36
| -13% | -$374 | ﹤0.01% | 6363 |
|
|
2016
Q4 | $2K | Buy |
+272
| New | +$2.98K | ﹤0.01% | 6487 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
Royal Bank of Canada's SNDX Position: Q2 2026 in Review
Royal Bank of Canada increased its Syndax Pharmaceuticals (SNDX) stake by 31% in Q2 2026, buying an estimated $149K and bringing the position to 30,555 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #4138.
Royal Bank of Canada first reported a position in SNDX in Q4 2016 and has held it in 35 quarters since. The position peaked at $3.51M in Q3 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- Royal Bank of Canada held 30,555 shares of Syndax Pharmaceuticals worth $667K as of Q2 2026.
- Royal Bank of Canada bought 7,174 Syndax Pharmaceuticals shares in Q2 2026, an estimated $149K.
- Syndax Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4138 holding.
- Royal Bank of Canada first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 35 quarters since.
- Royal Bank of Canada's Syndax Pharmaceuticals position peaked at $3.51M in Q3 2025.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.